U.S. pharma large copyright scrapped two experimental weight loss products past yr—a once-each day tablet, lotiglipron, on account of elevated liver enzymes along with a twice-daily pill, danuglipron, on account of solid side effects—but CEO Albert Bourla has claimed the company is d